gene editing edit gene CRISPR
Biotech

FDA illuminates new approval pathway for bespoke gene therapies

The new pathway—for now—focuses on genome editing and RNA-based methods that target the underlying cause of a rare disease.
Angus Liu , Darren Incorvaia Feb 23, 2026 11:30am
obesity overweight weight loss weigh

Novo's CagriSema loses phase 3 obesity battle against Zepbound

Feb 23, 2026 7:20am
GettyImages-2217220002jpg

iRegene Dual Firsts: US Dosing in PD Phase IIa, China MSA Enrollment

Feb 23, 2026 8:00am
Glowing puzzle piece fitting into puzzle

Gilead inks $8B Arcellx buyout to steer CAR-T into J&J showdown

Feb 23, 2026 7:30am
Quiver Arrow

Angelini nocks an AI arrow with $120M Quiver deal

Feb 23, 2026 11:04am
Cartoon of businessmen standing around a broken target

Gossamer Bio fails phase 3 pulmonary arterial hypertension trial

Feb 23, 2026 9:50am
More News

Generate plans $425M IPO to bankroll phase 3 asthma trials

Feb 23, 2026 9:42am

MoonLake arthritis win kicks off pivotal year for IL-17 nanobody

Feb 23, 2026 5:10am

Ionis scraps Alzheimer’s candidate for people with Down syndrome

Feb 20, 2026 1:50pm
Fierce Pharma

Supreme Court steps in: Trump's emergency tariffs struck down

Feb 20, 2026 11:33am